Bristol-Myers Squibb (BMY) Tops Q4 EPS by 28c, Offers FY Guidance, Approves $5B Buyback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019
February 6, 2020 7:05 AM ESTReports Fourth Quarter Revenues of $7.9 Billion; $26.1 Billion for Full Year Posts Fourth Quarter GAAP Loss Per Share of $0.55 and Non-GAAP EPS of $1.22 Completes Acquisition of Celgene; Integration and Synergy Capture on Track Presents Important New Data from Leading Hematology Portfolio at ASH Annual Meeting Announces Two U.S. FDA Filing Acceptances for Opdivo plus Yervoy Regimen Announces $5 Billion Increase to Share Repurchase Authorization Provides Financial Guidance for 2020 and 2021
NEW YORK--(BUSINESS... More
